Laboratory monitoring of new hemostatic agents for hemophilia
- 1 January 2016
- journal article
- review article
- Published by Elsevier BV in Seminars in Hematology
- Vol. 53 (1), 28-34
- https://doi.org/10.1053/j.seminhematol.2015.10.003
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice modelsBlood, 2013
- Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patientsBlood, 2012
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood, 2012
- Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsBlood, 2012
- Genetic fusion to albumin improves the pharmacokinetic properties of factor IXThrombosis and Haemostasis, 2009
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- A passionate kiss, then run: exocytosis and recycling of IgG by FcRnTrends in Cell Biology, 2005
- Consensus recommendations for use of central venous access devices in haemophiliaHaemophilia, 2004
- Coagulation and Chromogenic Assays of Factor VIII Activity: General Aspects, Standardization, and RecommendationsSeminars in Thrombosis and Hemostasis, 2002